Vir Biotechnology, Inc. (VIR)
| Previous close | 10.39 |
| Open | 10.46 |
| Bid | 10.37 x 100 |
| Ask | 10.42 x 100 |
| Day's range | 10.13 - 10.53 |
| 52-week range | 7.61 - 27.48 |
| Volume | |
| Avg. volume | 1,033,408 |
| Market cap | 1.409B |
| Beta (5Y monthly) | 0.41 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results
SAN FRANCISCO, May 02, 2024--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2024.
- Business Wire
Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024
SAN FRANCISCO, April 30, 2024--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is scheduled to participate in a fireside chat at the BofA Securities Healthcare Conference 2024 on Tuesday, May 14, at 4:20 p.m. PT / 7:20 p.m. ET.
- Business Wire
Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors
SAN FRANCISCO, April 18, 2024--Vir Biotechnology, Inc. ("Vir" or "the Company", Nasdaq: VIR) today announced the nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors (the "Board") at its upcoming annual meeting of stockholders on May 29, 2024 (the "Annual Meeting"). If elected, each of Drs. Bischofberger and Farid will join the Board on such date.
